Christina Rubenhag has been appointed Chief Financial Officer (CFO) of Boule Diagnostics and member of the Group Management Team. She succeeds Fredrik Alpsten who, as communicated earlier, will leave Boule to assume a position at another company. Christina Rubenhag will assume the position as of October 9.
Christina most recently served as CEO of Biolin Scientific Holding AB, a Swedish global instrumentation provider with 140 employees and 250 M SEK in revenues. Her previous roles have included CFO at Biolin Scientific Holding AB, Packetfront AB och Swe-Dish Satellite Systems AB. Christina holds a Bachelor of Science in Accounting from Umeå School of Business and Economics.
”We are very pleased that Christina is joining Boule, she brings solid experience from CFO roles, management team work and business leadership. With her strong drive and experience from business development she will contribute to developing Boule to the next level” says Fredrik Dalborg, CEO Boule Diagnostics.
For more information, please contact:
Fredrik Dalborg, CEO, Boule Diagnostics AB, phone +46 705-58 51 05
About Boule Diagnostics AB (publ)
Boule Diagnostics AB is a rapidly growing global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden and the USA. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. http://www.boule.se
This information is information that Boule Diagnostics AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, 08:45 CET September 20, 2017.